Epidemiology of cardiac amyloidosis in Germany: a retrospective analysis from 2009 to 2018.
Amyloid cardiomyopathy
Cardiac amyloidosis
Light-chain amyloidosis
Transthyretin amyloidosis
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
15
06
2022
accepted:
04
10
2022
pubmed:
15
10
2022
medline:
14
3
2023
entrez:
14
10
2022
Statut:
ppublish
Résumé
Improved imaging modalities contributed to increasing awareness of cardiac amyloidosis. Contemporary data on frequency trends in Germany are lacking. In a retrospective study using health claims data of a German statutory health insurance, patients with diagnostic codes of amyloidosis and concomitant heart failure between 2009 and 2018 were identified. Prevalence increased from 15.5 to 47.6 per 100,000 person-years, and incidence increased from 4.8 to 11.6 per 100,000 person-years, with a continuous steepening in the slope of incidence trend. In patients with amyloidosis and heart failure age and proportion of men significantly increased, whereas the frequency of myeloma and nephrotic syndrome significantly decreased over time. Median (IQR) survival time after first diagnosis was 2.5 years (0.5-6 years), with a 9% (95% CI 2-15%, p = 0.008) reduced risk of death in the second compared to the first 5 years of observation. In the 2 years prior and 1 year after diagnosis, mean total health care costs were 6568 €, 11,872 € and 21,955 € per person and year. The rise in cardiac amyloidosis has continuously accelerated in the last decade. Considering the adverse outcome and high health care burden, further effort should be put on early detection of the disease to implement available treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Improved imaging modalities contributed to increasing awareness of cardiac amyloidosis. Contemporary data on frequency trends in Germany are lacking.
METHODS
METHODS
In a retrospective study using health claims data of a German statutory health insurance, patients with diagnostic codes of amyloidosis and concomitant heart failure between 2009 and 2018 were identified.
RESULTS
RESULTS
Prevalence increased from 15.5 to 47.6 per 100,000 person-years, and incidence increased from 4.8 to 11.6 per 100,000 person-years, with a continuous steepening in the slope of incidence trend. In patients with amyloidosis and heart failure age and proportion of men significantly increased, whereas the frequency of myeloma and nephrotic syndrome significantly decreased over time. Median (IQR) survival time after first diagnosis was 2.5 years (0.5-6 years), with a 9% (95% CI 2-15%, p = 0.008) reduced risk of death in the second compared to the first 5 years of observation. In the 2 years prior and 1 year after diagnosis, mean total health care costs were 6568 €, 11,872 € and 21,955 € per person and year.
CONCLUSION
CONCLUSIONS
The rise in cardiac amyloidosis has continuously accelerated in the last decade. Considering the adverse outcome and high health care burden, further effort should be put on early detection of the disease to implement available treatment.
Identifiants
pubmed: 36241897
doi: 10.1007/s00392-022-02114-y
pii: 10.1007/s00392-022-02114-y
pmc: PMC9998316
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-408Informations de copyright
© 2022. The Author(s).
Références
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 135:1357–1377. https://doi.org/10.1161/CIRCULATIONAHA.116.024438
doi: 10.1161/CIRCULATIONAHA.116.024438
pubmed: 28373528
pmcid: 5392416
Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, Biagini E, Lorenzini M, Grigioni F, Leone O, Cappelli F, Palladini G, Rimessi P, Ferlini A, Arpesella G, Pinna AD, Merlini G, Perlini S (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J 34:520–528. https://doi.org/10.1093/eurheartj/ehs123
doi: 10.1093/eurheartj/ehs123
pubmed: 22745357
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140:16–26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169
doi: 10.1161/CIRCULATIONAHA.118.038169
pubmed: 31109193
Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol 68:161–172. https://doi.org/10.1016/j.jacc.2016.03.596
doi: 10.1016/j.jacc.2016.03.596
pubmed: 27386769
pmcid: 4940135
Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, Marwick TH, Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442–1448. https://doi.org/10.1136/heartjnl-2012-302353
doi: 10.1136/heartjnl-2012-302353
pubmed: 22865865
Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076–1084. https://doi.org/10.1016/j.jacc.2005.05.073
doi: 10.1016/j.jacc.2005.05.073
pubmed: 16168294
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AWJM, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404–2412. https://doi.org/10.1161/CIRCULATIONAHA.116.021612
doi: 10.1161/CIRCULATIONAHA.116.021612
pubmed: 27143678
González-López E, Gallego-Delgado M, Guzzo-Merello G, Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585–2594. https://doi.org/10.1093/eurheartj/ehv338
doi: 10.1093/eurheartj/ehv338
pubmed: 26224076
Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2:113–122. https://doi.org/10.1016/j.jchf.2013.11.004
doi: 10.1016/j.jchf.2013.11.004
pubmed: 24720917
pmcid: 3984539
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim J-S, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46–58. https://doi.org/10.1056/NEJMoa2028631
doi: 10.1056/NEJMoa2028631
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016. https://doi.org/10.1056/NEJMoa1805689
doi: 10.1056/NEJMoa1805689
pubmed: 30145929
Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, Seitzer J, O’Connell D, Walsh KR, Wood K, Phillips J, Xu Y, Amaral A, Boyd AP, Cehelsky JE, McKee MD, Schiermeier A, Harari O, Murphy A, Kyratsous CA, Zambrowicz B, Soltys R, Gutstein DE, Leonard J, Sepp-Lorenzino L, Lebwohl D (2021) CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl J Med 385:493–502. https://doi.org/10.1056/NEJMoa2107454
doi: 10.1056/NEJMoa2107454
pubmed: 34215024
Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S (2019) Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service medicare beneficiaries in the United States. Circ Heart Fail 12:e005407. https://doi.org/10.1161/CIRCHEARTFAILURE.118.005407
doi: 10.1161/CIRCHEARTFAILURE.118.005407
pubmed: 31170802
pmcid: 6557425
González-López E, Gagliardi C, Dominguez F, Quarta CC, Haro-Del MoralMilandri FJA, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, Garcia-Pavia P (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38:1895–1904. https://doi.org/10.1093/eurheartj/ehx043
doi: 10.1093/eurheartj/ehx043
pubmed: 28329248
Busse R, Blümel M, Knieps F, Bärnighausen T (2017) Statutory health insurance in Germany: a health system shaped by 135 years of solidarity, self-governance, and competition. The Lancet 390:882–897. https://doi.org/10.1016/S0140-6736(17)31280-1
doi: 10.1016/S0140-6736(17)31280-1
Westin O, Butt JH, Gustafsson F, Schou M, Salomo M, Køber L, Maurer M, Fosbøl EL (2021) Two decades of cardiac amyloidosis: a Danish nationwide study. JACC CardioOncol 3:522–533. https://doi.org/10.1016/j.jaccao.2021.05.004
doi: 10.1016/j.jaccao.2021.05.004
pubmed: 34729524
pmcid: 8543084
Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M (2021) Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the transthyretin amyloidosis outcomes survey. JACC CardioOncol 3:537–546. https://doi.org/10.1016/j.jaccao.2021.08.009
doi: 10.1016/j.jaccao.2021.08.009
pubmed: 34729526
pmcid: 8543133
Devesa A, Camblor Blasco A, Pello Lázaro AM, Askari E, Lapeña G, Gómez Talavera S, Taibo Urquía M, Rodríguez Olleros C, Tuñón J, Ibáñez B, Aceña Á (2021) Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail 8:2856–2865. https://doi.org/10.1002/ehf2.13360
doi: 10.1002/ehf2.13360
pubmed: 33963812
pmcid: 8318443
AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, Noseworthy PA, Johnson GB, Dunlay SM, Borlaug BA, Chareonthaitawee P, Roger VL, Dispenzieri A, Grogan M, Redfield MM (2021) Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol 6:1267–1274. https://doi.org/10.1001/jamacardio.2021.3070
doi: 10.1001/jamacardio.2021.3070
pubmed: 34431962
Palladini G, Milani P (2021) The quest for validated treatment endpoints in light chain (AL) amyloidosis: composite criteria for a composite disease. Leuk Lymphoma 62:1793–1794. https://doi.org/10.1080/10428194.2021.1913152
doi: 10.1080/10428194.2021.1913152
pubmed: 33879038
Okuda Y, Yamada T, Ueda M, Ando Y (2018) First nationwide survey of 199 patients with amyloid A amyloidosis in Japan. Intern Med 57:3351–3355. https://doi.org/10.2169/internalmedicine.1099-18
doi: 10.2169/internalmedicine.1099-18
pubmed: 30101921
pmcid: 6306533
Russo M, Obici L, Bartolomei I, Cappelli F, Luigetti M, Fenu S, Cavallaro T, Chiappini MG, Gemelli C, Pradotto LG, Manganelli F, Leonardi L, My F, Sampaolo S, Briani C, Gentile L, Stancanelli C, Di Buduo E, Pacciolla P, Salvi F, Casagrande S, Bisogni G, Calabrese D, Vanoli F, Di Iorio G, Antonini G, Santoro L, Mauro A, Grandis M, Di Girolamo M, Fabrizi GM, Pareyson D, Sabatelli M, Perfetto F, Rapezzi C, Merlini G, Mazzeo A, Vita G (2020) ATTRv amyloidosis Italian registry: clinical and epidemiological data. Amyloid 27:259–265. https://doi.org/10.1080/13506129.2020.1794807
doi: 10.1080/13506129.2020.1794807
pubmed: 32696671
Palladini G, Sachchithanantham S, Milani P, Gillmore J, Foli A, Lachmann H, Basset M, Hawkins P, Merlini G, Wechalekar AD (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126:612–615. https://doi.org/10.1182/blood-2015-01-620302
doi: 10.1182/blood-2015-01-620302
pubmed: 25987656
Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, Hanna M (2016) Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 67:2941–2948. https://doi.org/10.1016/j.jacc.2016.03.593
doi: 10.1016/j.jacc.2016.03.593
pubmed: 27339491
Bézard M, Kharoubi M, Galat A, Poullot E, Guendouz S, Fanen P, Funalot B, Moktefi A, Lefaucheur J-P, Abulizi M, Deux J-F, Gendre T, Audard V, El Karoui K, Canoui-Poitrine F, Zaroui A, Itti E, Teiger E, Planté-Bordeneuve V, Oghina S, Damy T (2021) Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. Eur J Heart Fail 23:264–274. https://doi.org/10.1002/ejhf.2028
doi: 10.1002/ejhf.2028
pubmed: 33094885
Grobe T, Szecsnyi J Arztreport 2021. https://www.bifg.de/publikationen/reporte/arztreport-2021 . Accessed 2 Jan 2022
Figueroa JF, Papanicolas I, Riley K, Abiona O, Arvin M, Atsma F, Bernal-Delgado E, Bowden N, Blankart CR, Deeny S, Estupiñán-Romero F, Gauld R, Haywood P, Janlov N, Knight H, Lorenzoni L, Marino A, Or Z, Penneau A, Shatrov K, van de Galien O, van Gool K, Wodchis W, Jha AK (2021) International comparison of health spending and utilization among people with complex multimorbidity. Health Serv Res 56(Suppl 3):1317–1334. https://doi.org/10.1111/1475-6773.13708
doi: 10.1111/1475-6773.13708
pubmed: 34350586
pmcid: 8579210
Dörr M, Riemer U, Christ M, Bauersachs J, Bosch R, Laufs U, Neumann A, Scherer M, Störk S, Wachter R (2021) Hospitalizations for heart failure: Still major differences between East and West Germany 30 years after reunification. ESC Heart Fail 8:2546–2555. https://doi.org/10.1002/ehf2.13407
doi: 10.1002/ehf2.13407
pubmed: 33949148
pmcid: 8318397
Hoffmann F, Icks A (2012) Unterschiede in der Versichertenstruktur von Krankenkassen und deren Auswirkungen für die Versorgungsforschung: Ergebnisse des Bertelsmann-Gesundheitsmonitors. Gesundheitswesen 74:291–297. https://doi.org/10.1055/s-0031-1275711
doi: 10.1055/s-0031-1275711
pubmed: 21755492
Sun AZ, Shu Y-H, Harrison TN, Hever A, Jacobsen SJ, O’Shaughnessy MM, Sim JJ (2020) Identifying patients with rare disease using electronic health record data: the Kaiser Permanente Southern California Membranous Nephropathy Cohort. Perm J. https://doi.org/10.7812/TPP/19.126
doi: 10.7812/TPP/19.126
pubmed: 32069207
pmcid: 7021143